Topic:

R&D

Latest Headlines

Latest Headlines

Google Ventures funds tablet for the elderly

Entrepreneur Keith Kocho is designing a smart tablet specifically for the elderly. He's been given $1 million from Google Ventures and Atlas Venture to work on the project.

Valeant rolls out prelim data on its newly purchased cancer vaccine Provenge

Valeant only just picked up Provenge from bankrupt Dendreon, but it's already trumpeting positive data for the flailing prostate cancer vaccine.

Illumina accelerator gets $40M cash infusion from hedge fund Viking Global

Illumina has revealed a new fund structure to back startup graduates from its accelerator that launched early last year. Dubbed Illumina Accelerator Boost Capital, the fund has secured an initial $40 million capital commitment from Viking Global Investors.

Ex-Merck Serono team bags €8.7M for PhI Parkinson's program

Prexton Therapeutics, the first company to emerge from the €30 million ($34 million) biotech-creation program Merck Serono set up amid the shuttering of its Geneva R&D center, has closed a Series A round.

Second Sight bionic eye viral video showcases restored patient vision

Allen Zderad lost his vision, but due to a bionic eye implant from a clinical trial, he regained the ability to see human forms and outlines of objects. The implant sends light wave signals to the optic nerve, compensating for a damaged retina.

In a medical first, three patients receive prosthetic hands in place of disabled ones

Imagine having your disabled hand replaced with a functional prosthetic one. It's a reality, The Lancet pronounced, at least for three Austrian men who suffered from injuries to the network of nerves that originate in the neck and control movement from the shoulder down to the hand.

U.K. readies dementia R&D investment fund

Few could fault the United Kingdom for aiming too low. Having seen its CNS R&D chops whittled away by Big Pharma cuts, the U.K. government has decided the best way out of the mire is to take aim at one of the trickiest fields of all with a multimillion-pound dementia R&D investment fund.

Takeda's betting on its pipeline to spur a long-awaited turnaround

Japanese giant Takeda Pharmaceutical is planning to finally return to growth next year, counting on its late-stage medicines to the lead charge.

AstraZeneca bets $122.5M on oral autoimmune drugs

AstraZeneca is out to get some more shots on goal in immunology, pairing up with a nascent biotech in hopes of developing oral medicines for psoriasis, arthritis and other diseases.

MIT team injects drug-carrying hydrogel that 're-heals' in the body

A team of MIT scientists has designed a new injectable hydrogel made from nanoparticles that could someday be used to hold drugs in the body, treating diseases such as cancer, macular degeneration and heart disease.